Skip to Main Content

We publish recommendations and resources, together with a host of other material for the benefit of our users.

SPS PGD template for the supply and/or administration of subcutaneous medroxyprogesterone acetate (SC-DMPA) injection for contraception.
SPS PGD template for the supply of combined hormonal transdermal patch for contraception.
SPS PGD template for the supply of combined hormonal vaginal ring for contraception.
SPS PGD template for the supply of a progestogen only pill (POP) for contraception.
SPS protocol template for the administration of lidocaine plus prilocaine cream to facilitate intrauterine device (IUD) insertion or removal.
SPS PGD template for the supply of a combined oral hormonal contraceptive for contraception, or for individuals requiring control of problematic bleeding.
SPS PGD template for administering intramuscular (IM) medroxyprogesterone acetate (DMPA) injection for contraception.
SPS protocol template for administration of lidocaine 10mg/ml spray to facilitate intrauterine device (IUD) insertion or removal.
SPS PGD template for the insertion of the Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception.
A template Quality Technical Agreement for outsourcing the receipt, storage, preparation and onward supply of marketed cryopreserved ATMPs.
Certain medicines require additional monitoring and dose adjustments when switching between solid dose and liquid formulations.
This document outlines key areas for focus of pharmaceutical expertise prior to an organisation implementing tissue engineered products.
This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of exagamglogene autotemcel.
This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing in-vivo genetically modified organism (GMO) gene therapy.
This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing ex-vivo genetically modified organism (GMO) gene therapy.
This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing ex-vivo non-genetically modified organism gene therapies.
This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.
This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing in-vivo non-genetically modified organism gene therapies.
New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
A resource collating the latest medication safety communications and publications to inform, support and inspire medication safety improvements.
A list of new product evaluations that are freely available to NHS staff.
Know what medicines are in the pipeline. Understand the strategic and operational challenges for the NHS. Start planning early.
A report on the state of the pharmacy technical services workforce in the North of England
A checklist for audits and self-inspections for the holders of wholesale distribution authorisations
SPS have developed a template audit tool to support organisations in auditing aspects of PGD development and use.
Advice on the use of Patient Group Directions (PGDs) to supply or administer a medication which is part of a clinical trial, study or pilot
E-learning developed by SPS in partnership with UKHSA, HEE and eLfH to support professionals who use, develop, authorise, review or update PGDs.